Literature DB >> 35113743

Unilateral Acute Idiopathic Maculopathy following Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2) Infection.

Ramesh Venkatesh1, Nikitha Gurram Reddy1, Pranjal Mishra1, Aditi Gupta1, Padmamalini Mahendradas2, Naresh Kumar Yadav1.   

Abstract

AIM: To report a case of unilateral acute idiopathic maculopathy (UAIM) following SARS-CoV-2 virus infection. CASE DESCRIPTION: A 44-year-old male patient, infected with SARS-CoV-2 virus previously, presented to the retina department with complaints of sudden blurring of vision in right eye. His presenting visual acuity in right eye was 20/30, N8. Fundus showed an irregular area of yellowish-white subretinal lesion at the macula involving the fovea with reddish-brown pigment clumps. Retinal imaging findings were consistent with the diagnosis of UAIM. No treatment was given.
RESULTS: The imaging findings showed improvement at day 7 post-presentation with improvement in vision to 20/20, N6. At final visit (5-week post presentation), visual acuity was maintained at 20/20, N6 and there was no recurrence of findings. EXPERT OPINION: Unilateral acute idiopathic maculopathy might be associated with SARS-CoV-2 virus infection.
CONCLUSION: Infection with SARS-CoV-2 virus might be associated with UAIM. Such an association has not yet been described in the literature.

Entities:  

Keywords:  COVID-19; SARS-CoV-2 virus; Unilateral acute idiopathic maculopathy

Year:  2022        PMID: 35113743     DOI: 10.1080/09273948.2022.2028287

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Acute idiopathic maculopathy after COVID-19 vaccination.

Authors:  Taiji Hasegawa; Yoka Sannomiya; Momoka Toyoda; Ichiro Maruko; Tomohiro Iida
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-09

2.  Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen.

Authors:  Xiuju Chen; Xiaoxin Li; Haibo Li; Minghan Li; Songjian Gong
Journal:  Vaccines (Basel)       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.